{"doc_id": "si-2021-0605-reg-1", "parent_doc_id": "si-2021-0605", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 605 of 2021", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2021, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n(Prescription and Control of Supply) (Amendment) (No. 13) Regulations 2021. \n\n(2) The collective citation “the Medicinal Products (Prescription and \n\nControl of Supply) Regulations 2003 to 2021” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 13) regulation 2021 (2) collective citation medicinal product (prescription control supply) regulation 2003 2021 includes regulation", "start_char": 620, "end_char": 910, "source_path": "downloads\\2021\\2021_0605.pdf", "extraction_method": "pdfminer", "checksum": "sha256:5d5127a0fc630477e547c5861a749a921547e8358bd8df02ee3da7722a2db3eb", "cross_refs": []}
{"doc_id": "si-2021-0605-reg-2", "parent_doc_id": "si-2021-0605", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 605 of 2021", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2021, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and \nControl of Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2021” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 12) Regulations 2021 (S.I. No. 578 of 2021).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2021 mean medicinal product (prescription control supply) (amendment) (no 12) regulation 2021 (s.i no 578 2021)", "start_char": 910, "end_char": 1226, "source_path": "downloads\\2021\\2021_0605.pdf", "extraction_method": "pdfminer", "checksum": "sha256:5d5127a0fc630477e547c5861a749a921547e8358bd8df02ee3da7722a2db3eb", "cross_refs": []}
{"doc_id": "si-2021-0605-reg-3", "parent_doc_id": "si-2021-0605", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 605 of 2021", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2021, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations \n\nof 2021) to the Principal Regulations is amended— \n\n(a) \n\nby substituting for the text in column 5 of the entry for the \nmedicinal product “Comirnaty concentrate for dispersion for \ninjection COVID-19 mRNA Vaccine (nucleoside modified)” the \nfollowing: \n\n“In accordance with the summary of product characteristics of \nthe product administered and relevant recommendations or \nguidelines issued by the National Immunisation Advisory \nCommittee and accepted by the Minister for Health. \n\nNotwithstanding any guidance to the contrary in the summary of \nproduct characteristics, an additional or booster dose may be \nadministered to— \n\n(a) \n\nimmunocompromised persons who are 12 years of age or \nolder, \n\n(b) persons who are 50 years of age or older, \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 23rd November, 2021. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[605] 3 \n\n(c) persons who reside in long term care facilities and are 16 \n\nyears of age or older, \n\n(d) persons who have underlying conditions associated with \nvery high risk or high risk of severe COVID-19 disease \nand are 16 years of age or older, and \n\n(e) health care workers, \nat such volumes, intervals and manner as may be specified in \nsuch recommendations or guidelines and subject to informed \nconsent being obtained.”, and \n\n(b) by substituting for the text in column 5 of the entry for the \nmedicinal product “Spikevax (previously Covid-19 Vaccine \nModerna) dispersion for injection COVID-19 mRNA Vaccine \n(nucleoside modified)” the following: \n\n“In accordance with the summary of product characteristics of \nthe product administered and relevant recommendations or \nguidelines issued by the National Immunisation Advisory \nCommittee and accepted by the Minister for Health. \nAn additional or booster dose may be administered to— \n(a) persons who are 50 years of age or older, and \n(b) persons who are 30 years of age or older and— \n\n(i) reside in long term care facilities, \n(ii) have underlying conditions associated with very high \nrisk or high risk of severe COVID-19 disease, or \n\n(iii) are health care workers, \n\nat such volumes, intervals and manner as may be specified in \nsuch recommendations or guidelines and subject to informed \nconsent being obtained.”.", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2021) principal regulation amended-- (a) substituting text column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance summary product characteristic product administered relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding guidance contrary summary product characteristic additional booster dose may administered to-- (a) immunocompromised person 12 year age older (b) person 50 year age older notice making statutory instrument published iris oifigiuil 23rd november 2021 605 3 (c) person reside long term care facility 16 year age older (d) person underlying condition associated high risk high risk severe covid-19 disease 16 year age older (e) health care worker volume interval manner may specified recommendation guideline subject informed consent obtained (b) substituting text column 5 entry medicinal product spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance summary product characteristic product administered relevant recommendation guideline issued national immunisation advisory committee accepted minister health additional booster dose may administered to-- (a) person 50 year age older (b) person 30 year age older and-- (i) reside long term care facility (ii) underlying condition associated high risk high risk severe covid-19 disease (iii) health care worker volume interval manner may specified recommendation guideline subject informed consent obtained", "start_char": 1226, "end_char": 3564, "source_path": "downloads\\2021\\2021_0605.pdf", "extraction_method": "pdfminer", "checksum": "sha256:5d5127a0fc630477e547c5861a749a921547e8358bd8df02ee3da7722a2db3eb", "cross_refs": []}
{"doc_id": "si-2021-0605-reg-4", "parent_doc_id": "si-2021-0605", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 605 of 2021", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2021, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \n\n2021) to the Principal Regulations is amended— \n\n(a) \n\nby substituting for the text in column 5 of the entry for the \nmedicinal product “Comirnaty concentrate for dispersion for \ninjection COVID-19 mRNA Vaccine (nucleoside modified)” the \nfollowing: \n\n“In accordance with the summary of product characteristics of \nthe product administered and relevant recommendations or \nguidelines issued by the National Immunisation Advisory \nCommittee and accepted by the Minister for Health. \nNotwithstanding any guidance to the contrary in the summary of \nproduct characteristics, an additional or booster dose may be \nadministered to— \n(a) \n\nimmunocompromised persons who are 12 years of age or \nolder, \n\n(b) persons who are 50 years of age or older, \n\n \n \n \n \n \n\f4 [605] \n\n(c) persons who reside in long term care facilities and are 16 \n\nyears of age or older, \n\n(d) persons who have underlying conditions associated with \nvery high risk or high risk of severe COVID-19 disease \nand are 16 years of age or older, and \n\n(e) health care workers, \nat such volumes, intervals and manner as may be specified in \nsuch recommendations or guidelines and subject to informed \nconsent being obtained.”, and \n\n(b) by substituting for the text in column 5 of the entry for the \nmedicinal product “Spikevax (previously Covid-19 Vaccine \nModerna) dispersion for injection COVID-19 mRNA Vaccine \n(nucleoside modified)” the following: \n\n“In accordance with the summary of product characteristics of \nthe product administered and relevant recommendations or \nguidelines issued by the National Immunisation Advisory \nCommittee and accepted by the Minister for Health. \nAn additional or booster dose may be administered to— \n(a) persons who are 50 years of age or older, and \n(b) persons who are 30 years of age or older and— \n\nreside in long term care facilities, \n\n(i) \n(ii) have underlying conditions associated with very \nhigh risk or high risk of severe COVID-19 disease, \nor \n\n(iii) are health care workers, \n\nat such volumes, intervals and manner as may be specified in \nsuch recommendations or guidelines and subject to informed \nconsent being obtained.”. \n\nGIVEN under my Official Seal, \n\n19 November, 2021. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n\f[605] 5", "text_norm": "4 twelfth schedule (as amended regulation 4 regulation 2021) principal regulation amended-- (a) substituting text column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance summary product characteristic product administered relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding guidance contrary summary product characteristic additional booster dose may administered to-- (a) immunocompromised person 12 year age older (b) person 50 year age older 4 605 (c) person reside long term care facility 16 year age older (d) person underlying condition associated high risk high risk severe covid-19 disease 16 year age older (e) health care worker volume interval manner may specified recommendation guideline subject informed consent obtained (b) substituting text column 5 entry medicinal product spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance summary product characteristic product administered relevant recommendation guideline issued national immunisation advisory committee accepted minister health additional booster dose may administered to-- (a) person 50 year age older (b) person 30 year age older and-- reside long term care facility (i) (ii) underlying condition associated high risk high risk severe covid-19 disease (iii) health care worker volume interval manner may specified recommendation guideline subject informed consent obtained  given official seal 19 november 2021 stephen donnelly minister health 605 5", "start_char": 3564, "end_char": 5902, "source_path": "downloads\\2021\\2021_0605.pdf", "extraction_method": "pdfminer", "checksum": "sha256:5d5127a0fc630477e547c5861a749a921547e8358bd8df02ee3da7722a2db3eb", "cross_refs": []}
{"doc_id": "si-2021-0605-explanatory-note", "parent_doc_id": "si-2021-0605", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 605 of 2021", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2021, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to amend the relevant schedules in relation \nto the Comirnaty and Spikevax COVID-19 vaccines to take account of updated \nNIAC advice in relation to booster and additional doses. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 13) Regulations 2021. \n\n \n \n \n \n \n \n \n \n\f6 [605] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-335) 75. 11/21. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation amend relevant schedule relation comirnaty spikevax covid-19 vaccine take account updated niac advice relation booster additional dos regulation may cited medicinal product (prescription control supply) (amendment) (no 13) regulation 2021 6 605 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-335) 75 11 21 propylon", "start_char": 5902, "end_char": 6985, "source_path": "downloads\\2021\\2021_0605.pdf", "extraction_method": "pdfminer", "checksum": "sha256:5d5127a0fc630477e547c5861a749a921547e8358bd8df02ee3da7722a2db3eb", "cross_refs": []}
